SEC Form 4 · accession 0001209191-18-049515
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Michel Halfon
Director
Period of report
Sep 5, 2018
Accepted (ET)
Sep 5, 2018 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Sep 3, 2018 | M | 2,162 | — | A | 2,162 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF2,F3,F1 | — | Sep 3, 2018 | M | 2,162 | D | — | — | Ordinary Shares | 2,162 | 0 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F3Restricted share units were granted on October 7, 2015 and vested on September 3, 2018.